EditForce, Inc. has entered into a license agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to research, develop and commercialize potential gene therapy products for a specific target disease related to the central nervous system (CNS) by utilizing EditForce’s pentatricopeptide repeat (PPR) protein platform technology.
MTPC and EditForce aim to create potential novel pharmaceuticals for the specific CNS disease by utilizing the drug R&D know-how and global business experience of MTPC and the novel biotechnology of EditForce.
MTPC will acquire the exclusive right to conduct the selection of drug candidate molecules, preclinical and clinical development, manufacturing, and commercialization worldwide.
Under the terms of the agreement, EditForce will receive an upfront payment and milestone payments amounting to more than 20 billion yen ($147.3 million), depending on the development stage and commercialization progress, and royalties based on worldwide sales after the launch.
“I am so delighted to reach the agreement with MTPC, which has an interest in our proprietary PPR protein platform technology,” said Takashi Ono, president and CEO of EditForce.
The post EditForce and Mitsubishi Tanabi Pharma to work on gene therapy for CNS appeared first on Labiotech.eu.
© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.